{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:22:39Z","timestamp":1773660159831,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1053\/beha.2002.0233","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T18:13:53Z","timestamp":1046801633000},"page":"757-769","source":"Crossref","is-referenced-by-count":17,"title":["Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts"],"prefix":"10.1053","volume":"15","author":[{"given":"Oliver G","family":"Ottmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Wassmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beha.2002.0233_RF1","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Glei\u03b2ner","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0889-8588(05)70198-2","article-title":"Philadelphia chromosome-positive acute lymphocytic leukemia. Advances in the treatment of adult acute lymphocytic leukemia","volume":"15","author":"Radich","year":"2001","journal-title":"Hematology and Oncology Clinics of North America"},{"key":"10.1053\/beha.2002.0233_RF3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","article-title":"Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"36","author":"Faderl","year":"2000","journal-title":"Leukemia and Lymphoma"},{"key":"10.1053\/beha.2002.0233_RF4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/325635a0","article-title":"A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"325","author":"Chan","year":"1987","journal-title":"Nature"},{"key":"10.1053\/beha.2002.0233_RF5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood.V68.6.1369.1369","article-title":"Bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia","volume":"68","author":"de Klein","year":"1986","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood.V73.5.1307.1307","article-title":"The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"73","author":"Heisterkamp","year":"1989","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.3541203","article-title":"Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL","volume":"235","author":"Clark","year":"1987","journal-title":"Science"},{"key":"10.1053\/beha.2002.0233_RF8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0233_RF9","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker-Walker","year":"1991","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0233_RF10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0950-3536(97)80004-2","article-title":"Signal transduction pathways involved in BCR-ABL transformation","volume":"10","author":"Sawyers","year":"1997","journal-title":"Bailli\u00e8re's Clinical Haematology"},{"key":"10.1053\/beha.2002.0233_RF11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/jnci\/91.2.102","article-title":"A Bcr\/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges","volume":"91","author":"Sausville","year":"1999","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1053\/beha.2002.0233_RF12","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Research"},{"key":"10.1053\/beha.2002.0233_RF13","first-page":"139","article-title":"Abl protein\u2013tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors (in process citation)","volume":"295","author":"Buchdunger","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapy"},{"key":"10.1053\/beha.2002.0233_RF14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nature Medicine"},{"key":"10.1053\/beha.2002.0233_RF15","first-page":"1661","article-title":"Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)","volume":"4","author":"Beran","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"10.1053\/beha.2002.0233_RF16","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0233_RF18","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF19","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2402770","article-title":"Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"16","author":"Wassmann","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0233_RF20","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood.V97.6.1572","article-title":"Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome","volume":"97","author":"Cornelissen","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF21","first-page":"589a","article-title":"Activity of the ABL tyrosine kinase inhibitor Glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) relapsing after allogeneic stem cell transplantation (abstract)","volume":"98","author":"Ottmann","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0889-8588(05)70188-X","article-title":"Treatment of Adult ALL according to protocols of the German Multicentre Study Group for Adult ALL (GMALL)","volume":"14","author":"G\u00f6kbuget","year":"2000","journal-title":"Hematology and Oncology Clinics of North America"},{"key":"10.1053\/beha.2002.0233_RF23","first-page":"951","article-title":"Prevention of meningeal leukemia. Review of 20 years of research and current recommendations","volume":"4","author":"Pochedly","year":"1990","journal-title":"Hematology and Oncology Clinics of North America"},{"key":"10.1053\/beha.2002.0233_RF24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.2830430104","article-title":"High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia","volume":"43","author":"Saikia","year":"1993","journal-title":"American Journal of Hematology"},{"key":"10.1053\/beha.2002.0233_RF25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<205::AID-CNCR28>3.0.CO;2-7","article-title":"Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report","volume":"88","author":"Stark","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/beha.2002.0233_RF26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1005963732481","article-title":"Meningeosis leukaemica in adult acute lymphoblastic leukaemia","volume":"38","author":"G\u00f6kbuget","year":"1998","journal-title":"Journal of Neurooncology"},{"key":"10.1053\/beha.2002.0233_RF27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-2141.2002.03523.x","article-title":"Low concentrations of STI571 in the cerebrospinal fluid: a case report","volume":"117","author":"Petzer","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1053\/beha.2002.0233_RF28","first-page":"140a.","article-title":"Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL (abstract)","volume":"98","author":"Leis","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF29","first-page":"637","article-title":"Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission","volume":"17","author":"Singhal","year":"1996","journal-title":"Bone Marrow Transplantion"},{"key":"10.1053\/beha.2002.0233_RF30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beha.2002.0233_RF31","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Glivec\u2122 (imatinib mesylate) induces haematological and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF32","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF33","first-page":"87a","article-title":"Imatinib Mesylate (Glivec\u2122, STI-571) in Patients with Relapsed or Refractory Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL): Extended Follow-Up and Analysis of Prognostic Factors (abstract)","volume":"100","author":"Wassmann","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1535-6108(02)00101-0","article-title":"Resistance in the land of molecular cancer therapeutics","volume":"2","author":"Shannon","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/beha.2002.0233_RF36","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukaemic cells to the abl inhibitor STI571","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1053\/beha.2002.0233_RF37","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukaemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF38","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/beha.2002.0233_RF41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1053\/beha.2002.0233_RF42","doi-asserted-by":"crossref","first-page":"2163a","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI\u2013571 cancer therapy","volume":"293","author":"Hochhaus","year":"2001","journal-title":"Science"},{"key":"10.1053\/beha.2002.0233_RF43","doi-asserted-by":"crossref","first-page":"2163a","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of Clinical resistance to STI\u2013571 cancer therapy","volume":"293","author":"Barthe","year":"2001","journal-title":"Science"},{"key":"10.1053\/beha.2002.0233_RF44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome\/Bcr-Abl positive acute lymphoblastic leukemia (Ph+ALL) with the Abl-tyrosine kinase inhibitor STI571 (Glivec)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF45","first-page":"593","article-title":"A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia (abstract)","volume":"98","author":"O'Brien","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF46","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF47","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2402041","article-title":"Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells","volume":"15","author":"Topaly","year":"2001","journal-title":"Leukemia"},{"key":"10.1053\/beha.2002.0233_RF49","first-page":"802a","article-title":"Combination of Hyper-CVAD with Imatinib Mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP) (abstract)","volume":"98","author":"Thomas","year":"2001","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF50","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","article-title":"Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336","volume":"100","author":"Hoover","year":"2002","journal-title":"Blood"},{"key":"10.1053\/beha.2002.0233_RF51","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","article-title":"Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571","volume":"21","author":"Klejman","year":"2002","journal-title":"Oncogene"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692602902331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T19:49:30Z","timestamp":1584474570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692602902331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S1521692602902331"],"URL":"https:\/\/doi.org\/10.1053\/beha.2002.0233","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}